
A Mount Sinai-led research team has demonstrated that autoimmunity, in which the body’s immune system attacks its own tissues, is responsible for the often-debilitating and confounding symptoms of long COVID in a subset of people.
Findings from the study, published in Cell, could lead to important new approaches to treating patients with long COVID, including already-validated therapies for management of autoimmunity as well as new ways of clinically identifying which patients are most likely to benefit from these therapies.
Autoimmunity emerges as key driver
“We’ve known for some time that long COVID involves not just one but a variety of phenotypes, and now we have validated that autoimmunity is a major contributor to the symptom burden,” says David Putrino, Ph.D...












Recent Comments